

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



KINGWORLD MEDICINES GROUP LIMITED
金活醫藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code : 01110)

CONTINUING CONNECTED TRANSACTIONS

**PROPOSED ANNUAL CAPS
FOR THE THREE YEARS ENDING 31 DECEMBER 2022**

Reference is made to the announcement of the Company dated 11 December 2018 in respect of certain continuing connected transactions with Yuen Tai and SZ Kingworld Lifeshine contemplated under the 2019 Yuen Tai Master Distribution Agreement and the 2019 SZ Kingworld Lifeshine Master Distribution Agreement, respectively.

2020 YUEN TAI MASTER DISTRIBUTION AGREEMENT AND 2020 SZ KINGWORLD LIFESHINE MASTER DISTRIBUTION AGREEMENT

In view of the prospective expiry of the 2019 Yuen Tai Master Distribution Agreement and the 2019 SZ Kingworld Lifeshine Master Distribution Agreement, on 20 November 2019 (after trading hours), (1) HK Kingworld, a wholly-owned subsidiary of the Company, entered into the 2020 Yuen Tai Master Distribution Agreement with Yuen Tai for the purchase of the Yuen Tai Products for the three years ending 31 December 2022, and (2) SZ Kingworld, a wholly-owned subsidiary of the Company, entered into the 2020 SZ Kingworld Lifeshine Master Distribution Agreement with SZ Kingworld Lifeshine for the purchase of the SZ Kingworld Lifeshine Products for the three years ending 31 December 2022.

IMPLICATIONS UNDER THE LISTING RULES

Both Yuen Tai and SZ Kingworld Lifeshine are companies wholly-owned by Morning Gold, which is in turn 51% held by Mr. Zhao and 49% held by Ms. Chan, respectively. Both of Mr. Zhao and Ms. Chan are executive Directors and Controlling Shareholders of the Company. Therefore, each of Yuen Tai and SZ Kingworld Lifeshine is a connected person of the Company and the transactions under each of the 2020 Master Distribution Agreements constitute continuing connected transactions of the Company under Chapter 14A of the Listing Rules.

Given that the transactions contemplated under the 2020 Master Distribution Agreements are to be made with Yuen Tai and SZ Kingworld Lifeshine, and these two companies are indirectly wholly-owned by Mr. Zhao and Ms. Chan, such transactions shall be aggregated in accordance with Rule 14A.81 of the Listing Rules.

Since one or more of the applicable percentage ratios in respect of the aggregate of the proposed annual caps for the transactions contemplated under the 2020 Master Distribution Agreements is/are expected to exceed 5%, the transactions thereunder are subject to the reporting, announcement, annual review, circular and Independent Shareholders' approval requirements under Chapter 14A of the Listing Rules.

The Independent Financial Adviser has been appointed to advise the Independent Board Committee and the Independent Shareholders, and the Independent Board Committee has been established to advise the Independent Shareholders in respect of the transactions under each of the 2020 Master Distribution Agreements and their respective proposed annual caps for the three years ending 31 December 2022.

A circular containing, among other things, (i) details of the transactions under each of the 2020 Master Distribution Agreements as set out in this announcement and the proposed annual caps thereof; (ii) a letter from the Independent Financial Adviser to the Independent Board Committee and the Independent Shareholders containing its advice on the 2020 Master Distribution Agreements and the proposed annual caps thereof; (iii) recommendation of the Independent Board Committee to the Independent Shareholders; and (iv) the notice convening the EGM will be despatched to the Shareholders on or before 10 December 2019, which is within 15 Business Days after the publication of this announcement.

A. Background

Reference is made to the announcement of the Company dated 11 December 2018 in respect of certain continuing connected transactions with Yuen Tai and SZ Kingworld Lifeshine contemplated under the 2019 Yuen Tai Master Distribution Agreement and the 2019 SZ Kingworld Lifeshine Master Distribution Agreement, respectively.

In view of the prospective expiry of the 2019 Yuen Tai Master Distribution Agreement and the 2019 SZ Kingworld Lifeshine Master Distribution Agreement, on 20 November 2019 (after trading hours), (1) HK Kingworld, a wholly-owned subsidiary of the Company, entered into the 2020 Yuen Tai Master Distribution Agreement with Yuen Tai for the purchase of the Yuen Tai Products for the three years ending 31 December 2022, and (2) SZ Kingworld, a wholly-owned subsidiary of the Company, entered into the 2020 SZ Kingworld Lifeshine Master Distribution Agreement with SZ Kingworld Lifeshine for the purchase of the SZ Kingworld Lifeshine Products for the three years ending 31 December 2022.

Details of the 2020 Master Distribution Agreements are as follows:

B. 2020 Yuen Tai Master Distribution Agreement

1. Date: 20 November 2019

2. Parties:

(a) HK Kingworld, a wholly-owned subsidiary of the Company

(b) Yuen Tai

3. Description of the transactions:

Pursuant to the 2020 Yuen Tai Master Distribution Agreement, HK Kingworld has agreed to purchase the Yuen Tai Products from Yuen Tai and act as the exclusive distributor for distribution of the Yuen Tai Products in the Greater China.

4. Condition precedent:

The 2020 Yuen Tai Master Distribution Agreement shall take effect subject to and conditional upon obtaining the Independent Shareholders' approval in respect of the 2020 Yuen Tai Master Distribution Agreement and the proposed annual caps for the transactions under the agreement.

5. Term:

The 2020 Yuen Tai Master Distribution Agreement is for a term of three years with effect from 1 January 2020 and ending on 31 December 2022 (both days inclusive).

6. Pricing and payment terms:

The 2020 Yuen Tai Master Distribution Agreement was negotiated and entered into on an arm's length basis and on normal commercial terms. The terms and conditions (including but not limited to the prices) on which the Yuen Tai Products are to be purchased by the Group should be on normal commercial terms and no less favourable than those obtained from independent third parties by the Group. The Group will satisfy the consideration of such purchases by its internal resources.

The prices of the Yuen Tai Products to be purchased by the Group will be based on the prevailing market prices of similar products and the unit prices of the Yuen Tai Products from time to time and will be no less favourable to the Group than those terms offered by other independent third parties suppliers.

The actual amounts, types, unit prices, delivery dates and methods of delivery of the Yuen Tai Products to the Group will be subject to individual orders placed by the Group and accepted by Yuen Tai. To the extent that a comparison can be made (subject to similar nature, quality, quantity of purchase and conditions of the products and/or services), the Company and/or HK Kingworld shall use its best efforts to obtain price quotations from at least two independent third parties for comparison purposes (if applicable), to determine whether the prices and/or terms offered by Yuen Tai are fair and reasonable, and are similar to or more favourable than those offered by the independent third party(ies). The Group shall have the right to terminate or cancel the transactions if the terms and conditions are less favourable to the Group than those offered by other independent third parties suppliers.

40% of the purchase price shall be paid in advance by the Group within three days after the Group has placed an order for each batch of products and the remaining balance of the purchase price shall be paid upon delivery of the products and the passing of the product inspection.

7. Historical transaction amounts:

Set out below are the historical transaction amounts between the Group and Yuen Tai in respect of the purchase and distribution of Yuen Tai Products under the 2017 Yuen Tai Mater Distribution Agreement for the year ended 31 December 2017, under the 2018 Yuen Tai Master Distribution Agreement for the year ended 31 December 2018 and under the 2019 Yuen Tai Master Distribution Agreement for the ten months ended 31 October 2019, the annual caps under the 2017 Yuen Tai Master Distribution Agreement for the year ended 31 December 2017, under the 2018 Yuen Tai Master Distribution Agreement for the year ended 31 December 2018 and under the 2019 Yuen Tai Master Distribution Agreement for the year ending 31 December 2019:

	Audited transaction amount for the year ended 31 December 2017	Annual cap for the year ended 31 December 2017	Audited transaction amount for the year ended 31 December 2018	Annual cap for the year ended 31 December 2018	Unaudited transaction amount for the ten months ended 31 October 2019	Annual cap for the year ending 31 December 2019
Purchase of Yuen Tai Products	HK\$3,739,000	HK\$6,320,000	HK\$15,000 <i>(equivalent to approximately)</i>	HK\$8,900,000	HK\$nil	HK\$3,670,000
	RMB3,175,000	RMB5,366,000	RMB13,000	RMB7,556,000	RMBnil	RMB3,233,000

8. Proposed annual caps:

Set out below are the proposed annual caps under the 2020 Yuen Tai Master Distribution Agreement for the three years ending 31 December 2022:

	Annual cap for the year ending 31 December 2020	Annual cap for the year ending 31 December 2021	Annual cap for the year ending 31 December 2022
Purchase of Yuen Tai Products	HK\$4,740,000	HK\$9,968,000	HK\$13,781,000
	<i>(equivalent to approximately)</i>		
	RMB4,242,000	RMB8,921,000	RMB12,334,000

In arriving at the above proposed annual caps, the Directors have taken into account the following factors:

- (i) the historical figures of the actual transaction amounts of the transactions under the 2017 Yuen Tai Master Distribution Agreement for the year ended 31 December 2017, under the 2018 Yuen Tai Master Distribution Agreement for the year ended 31 December 2018 and under the 2019 Yuen Tai Master Distribution Agreement for the ten months ended 31 October 2019. The Directors are of the view that there was no transaction under the 2019 Yuen Tai Master Distribution Agreement for the ten months ended 31 October 2019 due to the delay in obtaining production certification by Yuen Tai for the supply of the Yuen Tai Products, which was an uncontrollable one-off incident. The related production certification was obtained in early November 2019; and
- (ii) the expected demand for different pharmaceutical and healthcare products from customers.

C. 2020 SZ Kingworld Lifeshine Master Distribution Agreement

1. **Date:** 20 November 2019

2. **Parties:**

- (a) SZ Kingworld, a wholly-owned subsidiary of the Company
- (b) SZ Kingworld Lifeshine

3. **Description of the transactions:**

Pursuant to the 2020 SZ Kingworld Lifeshine Master Distribution Agreement, SZ Kingworld has agreed to purchase the SZ Kingworld Lifeshine Products from SZ Kingworld Lifeshine and act as the exclusive distributor for distribution of the SZ Kingworld Lifeshine Products in the Greater China.

4. Condition precedent:

The 2020 SZ Kingworld Lifeshine Master Distribution Agreement shall take effect subject to and conditional upon obtaining the Independent Shareholders' approval in respect of the 2020 SZ Kingworld Lifeshine Master Distribution Agreement and the proposed annual caps for the transactions under the agreement.

5. Term:

The 2020 SZ Kingworld Lifeshine Master Distribution Agreement is for a term of three years with effect from 1 January 2020 and ending on 31 December 2022 (both days inclusive).

6. Pricing and payment terms:

The 2020 SZ Kingworld Lifeshine Master Distribution Agreement was negotiated and entered into on an arm's length basis and on normal commercial terms. The terms and conditions (including but not limited to the prices) on which the SZ Kingworld Lifeshine Products are to be purchased by the Group should be on normal commercial terms and no less favourable than those obtained from independent third parties by the Group. The Group will satisfy the consideration of such purchases by its internal resources.

The prices of the SZ Kingworld Lifeshine Products to be purchased by the Group will be based on the prevailing market prices of similar products and the unit prices of the SZ Kingworld Lifeshine Products as from time to time and will be no less favourable to the Group than those terms offered by other independent third parties suppliers.

The actual amounts, types, unit prices, delivery dates and methods of delivery of the SZ Kingworld Lifeshine Products to the Group will be subject to individual orders placed by the Group and accepted by SZ Kingworld Lifeshine. To the extent that a comparison can be made (subject to similar nature, quality, quantity of purchase and conditions of the products and/or services), the Company and/or SZ Kingworld shall use its best efforts to obtain price quotations from at least two independent third parties for comparison purposes (if applicable), to determine whether the prices and/or terms offered by SZ Kingworld Lifeshine are fair and reasonable, and are similar to or more favourable than those offered by the independent third party(ies). The Group shall have the right to terminate or cancel the transactions if the terms and conditions are less favourable to the Group than those offered by other independent third parties suppliers.

40% of the purchase price shall be paid in advance by the Group within three days after the Group has placed an order for each batch of products and the remaining balance of the purchase price shall be paid upon delivery of the products and the passing of the product inspection.

7. Historical transaction amounts:

Set out below are the historical transaction amounts between the Group and SZ Kingworld Lifeshine in respect of the purchase and distribution of SZ Kingworld Lifeshine Products under the 2017 SZ Kingworld Lifeshine Master Distribution Agreement for the year ended 31 December 2017, under the 2018 SZ Kingworld Lifeshine Master Distribution Agreement for the year ended 31 December 2018 and under the 2019 SZ Kingworld Lifeshine Master Distribution Agreement for the ten months ended 31 October 2019, the annual caps under the 2017 SZ Kingworld Lifeshine Master Distribution Agreement for the year ended 31 December 2017, under the 2018 SZ Kingworld Lifeshine Master Distribution Agreement for the year ended 31 December 2018 and under the 2019 SZ Kingworld Lifeshine Master Distribution Agreement for the year ending 31 December 2019:

	Audited transaction amount for the year ended 31 December 2017	Annual cap for the year ended 31 December 2017	Audited transaction amount for the year ended 31 December 2018	Annual cap for the year ended 31 December 2018	Unaudited transaction amount for the ten months ended 31 October 2019	Annual cap for the year ending 31 December 2019
Purchase of SZ Kingworld Lifeshine Products	RMB9,187,000	RMB24,340,000	RMB11,664,000	RMB21,910,000	RMB10,839,000	RMB20,400,000
	HK\$10,618,000	HK\$27,748,000	HK\$13,817,000	HK\$25,807,000	HK\$12,232,000	HK\$23,156,000
			<i>(equivalent to approximately)</i>			

8. Proposed annual caps:

Set out below are the proposed annual caps under the 2020 SZ Kingworld Lifeshine Master Distribution Agreement for the three years ending 31 December 2022:

	Annual cap for the year ending 31 December 2020	Annual cap for the year ending 31 December 2021	Annual cap for the year ending 31 December 2022
Purchase of SZ Kingworld Lifeshine Products	RMB22,271,000	RMB24,498,000	RMB26,948,000
	HK\$24,884,000	HK\$27,372,000	HK\$30,110,000
		<i>(equivalent to approximately)</i>	

In arriving at the above proposed annual caps, the Directors have taken into account the following factors:

- (i) the historical figures of the actual transaction amounts of the transactions under the 2017 SZ Kingworld Lifeshine Master Distribution Agreement for the year ended 31 December 2017, under the 2018 SZ Kingworld Lifeshine Master Distribution Agreement for the year ended 31 December 2018 and under the 2019 SZ Kingworld Lifeshine Master Distribution Agreement for the ten months ended 31 October 2019; and
- (ii) the expected demand for different pharmaceutical and healthcare products from customers.

D. REASONS FOR AND BENEFITS IN ENTERING INTO THE 2020 MASTER DISTRIBUTION AGREEMENTS

The Group is principally engaged in the distribution of pharmaceutical and healthcare products in the PRC. The pharmaceutical and healthcare products distributed by the Group are supplied by various suppliers including Yuen Tai and SZ Kingworld Lifeshine. The Directors consider that a long term and steady relationship with these suppliers are of importance to the Group as it enables stability in the supply to the Group which in turn avoids any unnecessary disruption to the Group's business and guarantees a smooth operation of the Group. By entering into the 2020 Master Distribution Agreements, the Group can maintain long term relationships with Yuen Tai and SZ Kingworld Lifeshine.

Pursuant to the 2020 Master Distribution Agreements, the products to be purchased by the Group are on an exclusive basis and the prices of such products should be on normal commercial terms and no less favourable than those obtained from independent third parties. As such, the Group may gain competitive advantage in terms of costs. As the Group will act as the exclusive distributor for distribution of such products in the Greater China, the Group may avoid competition with other distributors with respect to the same products in the market.

In light of the above factors, the Directors (excluding Mr. Zhao and Ms. Chan, who have abstained from voting on the relevant board resolutions due to their interest in the 2020 Master Distribution Agreements and the independent non-executive Directors) consider that the terms under each of the 2020 Master Distribution Agreements and their respective proposed annual caps for the three years ending 31 December 2022 are fair and reasonable and in the interests of the Shareholders as a whole. The opinion of the independent non-executive Directors will be formed after taking into account the advice to be provided by the Independent Financial Adviser, which will be set out in the circular to be despatched to the Shareholders on or before 10 December 2019.

E. GENERAL INFORMATION

1. Principal Business Activities

a) *The Group*

The Group is principally engaged in the distribution of pharmaceutical and healthcare products in the PRC and Hong Kong.

b) *Yuen Tai*

Yuen Tai is principally engaged in the manufacturing of pharmaceutical and healthcare products.

c) *SZ Kingworld Lifeshine*

SZ Kingworld Lifeshine is principally engaged in the manufacturing of pharmaceutical and healthcare products.

F. IMPLICATIONS UNDER THE LISTING RULES

Both Yuen Tai and SZ Kingworld Lifeshine are companies wholly-owned by Morning Gold, which is in turn 51% held by Mr. Zhao and 49% held by Ms. Chan, respectively. Both of Mr. Zhao and Ms. Chan are executive Directors and Controlling Shareholders of the Company. Therefore, each of Yuen Tai and SZ Kingworld Lifeshine is a connected person of the Company and the transactions under each of the 2020 Master Distribution Agreements constitute continuing connected transactions of the Company under Chapter 14A of the Listing Rules.

Given that the transactions contemplated under the 2020 Master Distribution Agreements are to be made with Yuen Tai and SZ Kingworld Lifeshine, and these two companies are indirectly wholly-owned by Mr. Zhao and Ms. Chan, such transactions shall be aggregated in accordance with Rule 14A.81 of the Listing Rules.

Since one or more of the applicable percentage ratios in respect of the aggregate of the proposed annual caps for the transactions contemplated under the 2020 Master Distribution Agreements is/are expected to exceed 5%, the transactions thereunder are subject to the reporting announcement, annual review, circular and Independent Shareholders' approval requirements under Chapter 14A of the Listing Rules.

The Company confirms that the transactions contemplated under the 2020 Master Distribution Agreements are of a revenue nature in the ordinary and usual course of business of the Company and therefore are exempted from the requirements under Chapter 14 of the Listing Rules.

Other than Mr. Zhao and Ms. Chan, no Director is materially interested in the transactions under each of the 2020 Master Distribution Agreements and is required to abstain from voting on the Board resolutions to approve such agreements.

The Company will convene the EGM to obtain the approval from the Independent Shareholders in respect of the 2020 Master Distribution Agreements and their respective proposed annual caps for the three years ending 31 December 2022.

As Mr. Zhao and Ms. Chan have a material interest in the 2020 Master Distribution Agreements and the transactions contemplated thereunder, Mr. Zhao and Ms. Chan and their associates are required under the Listing Rules to abstain from voting on the relevant resolutions at the EGM in respect of the 2020 Master Distribution Agreements and their respective proposed annual caps for the three years ending 31 December 2022.

The Independent Financial Adviser has been appointed to advise the Independent Board Committee and the Independent Shareholders, and the Independent Board Committee has been established to advise the Independent Shareholders in respect of the transactions under each of the 2020 Master Distribution Agreements and their respective proposed annual caps for the three years ending 31 December 2022.

A circular containing, among other things, (i) details of the transactions under each of the 2020 Master Distribution Agreements as set out in this announcement and the proposed annual caps thereof; (ii) a letter from the Independent Financial Adviser to the Independent Board Committee and the Independent Shareholders containing its advice on the 2020 Master Distribution Agreements and the proposed annual caps thereof; (iii) recommendation of the Independent Board Committee to the Independent Shareholders; and (iv) the notice convening the EGM will be despatched to the Shareholders on or before 10 December 2019, which is within 15 Business Days after the publication of this announcement.

G. DEFINITIONS

In this announcement, unless the context otherwise requires, the following terms shall have the following meanings:

“2017 SZ Kingworld Lifeshine Master Distribution Agreement”	the master distribution agreement dated 1 December 2016 entered into between SZ Kingworld and SZ Kingworld Lifeshine for the purchase of the SZ Kingworld Lifeshine Products for the year ended 31 December 2017
“2017 Yuen Tai Master Distribution Agreement”	the master distribution agreement dated 1 December 2016 entered into between HK Kingworld and Yuen Tai for the purchase of the Yuen Tai Products for the year ended 31 December 2017, as revised and supplemented by the Supplemental Agreement
“2018 SZ Kingworld Lifeshine Master Distribution Agreement”	the master distribution agreement dated 14 December 2017 entered into between SZ Kingworld and SZ Kingworld Lifeshine for the purchase of the SZ Kingworld Lifeshine Products for the year ended 31 December 2018

“2018 Yuen Tai Master Distribution Agreement”	the master distribution agreement dated 14 December 2017 entered into between HK Kingworld and Yuen Tai for the purchase of the Yuen Tai Products for the year ended 31 December 2018
“2019 SZ Kingworld Lifeshine Master Distribution Agreement”	the master distribution agreement dated 11 December 2018 entered into between SZ Kingworld and SZ Kingworld Lifeshine for the purchase of the SZ Kingworld Lifeshine Products for the year ending 31 December 2019
“2019 Yuen Tai Master Distribution Agreement”	the master distribution agreement dated 11 December 2018 entered into between HK Kingworld and Yuen Tai for the purchase of the Yuen Tai Products for the year ending 31 December 2019
“2020 Master Distribution Agreements”	collectively, (i) the 2020 Yuen Tai Master Distribution Agreement; and (ii) the 2020 SZ Kingworld Lifeshine Master Distribution Agreement
“2020 SZ Kingworld Lifeshine Master Distribution Agreement”	the master distribution agreement dated 20 November 2019 entered into between SZ Kingworld and SZ Kingworld Lifeshine for the purchase of the SZ Kingworld Lifeshine Products for the three years ending 31 December 2022
“2020 Yuen Tai Master Distribution Agreement”	the master distribution agreement dated 20 November 2019 entered into between HK Kingworld and Yuen Tai for the purchase of the Yuen Tai Products for the three years ending 31 December 2022
“associate”	has the meaning ascribed to it under the Listing Rules
“Board”	the board of directors of the Company
“Business Day(s)”	a day other than a Saturday, Sunday or public holiday (or a day on which a tropical cyclone No.8 or above or a “black” rainstorm warning is hoisted in Hong Kong at any time between 9:00 a.m. and 5:00 p.m. on weekdays) on which banks are open in Hong Kong to the general public for business
“Company”	Kingworld Medicines Group Limited (金活醫藥集團有限公司), a company incorporated in the Cayman Islands with limited liability, the shares of which are listed on the Main Board of the Stock Exchange
“connected person(s)”	has the meaning ascribed to it under the Listing Rules
“Controlling Shareholder(s)”	has the meaning ascribed to it under the Listing Rules
“Director(s)”	the director(s) of the Company

“Dual-Specification”	a classification of pharmaceutical product which can be sold pursuant to the requirement as for either prescription or OTC pharmaceutical products
“EGM”	an extraordinary general meeting of the Company to be convened for the purpose of considering, and if thought fit, approving the 2020 Master Distribution Agreements and their respective proposed annual caps for the three years ending 31 December 2022
“Fengbao Jianfu Capsule”	Fengbao Jianfu Capsule (鳳寶牌健婦膠囊), a Dual-Specification pharmaceutical product manufactured in Hong Kong and imported from Yuen Tai
“GMP”	Good Manufacturing Practices, the practices required in order to conform to the guidelines recommended by agencies that control authorisation and licensing for manufacture and sale of food, drug products and active pharmaceutical products
“Greater China”	the PRC, including Hong Kong, Macao Special Administrative Region of the PRC and Taiwan
“Group”	the Company and its subsidiaries
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“HK Kingworld”	Kingworld Medicine Healthcare Limited (金活藥業健康發展有限公司), a limited liability company incorporated under the laws of Hong Kong and a wholly-owned subsidiary of the Company
“Hong Kong”	The Hong Kong Special Administrative Region of the PRC
“Imada Red Flower Oil”	Imada Red Flower Oil (依馬打正紅花油), a prescribed pharmaceutical product distributed by the Group
“Independent Board Committee”	a committee of the Board comprising all the independent non-executive Directors, namely, Mr. Duan Jidong, Mr. Zhang Jianbin and Mr. Wong Cheuk Lam
“Independent Financial Adviser”	Vinco Capital Limited, a licensed corporation to conduct type 1 (dealing in securities) and type 6 (advising on corporate finance) regulated activities under the SFO, which is appointed to advise the Independent Board Committee and the Independent Shareholders in respect of the 2020 Yuen Tai Master Distribution Agreement, the 2020 SZ Kingworld Lifeshine Master Distribution Agreement and the proposed annual caps for the transactions under each of these agreements

“Independent Shareholder(s)”	the Shareholder(s), other than those required by the Listing Rules to abstain from voting on the resolutions to be proposed at the EGM in relation to the 2020 Master Distribution Agreements and accordingly, the proposed annual caps for the continuing connected transactions contemplated thereunder
“Kingworld Product Range”	products including but not limited to Kingworld Gan Mao Qing Capsule (金活感冒清膠囊) and products under the Kingworld American Ginseng series (金活洋參系列)
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“Morning Gold”	Morning Gold Medicine Company Limited (金辰醫藥有限公司), a limited liability company incorporated under the laws of Hong Kong
“Mr. Zhao”	Zhao Li Sheng (趙利生), the chairman, an executive Director, a co-founder and Controlling Shareholder of the Company
“Ms. Chan”	Chan Lok San (陳樂燊), an executive Director, a co-founder and Controlling Shareholder of the Company
“OTC”	over the counter, a classification of pharmaceutical product which can be obtained without any doctors’ prescriptions. In the PRC, OTC products are further classified into “OTC (A)” and “OTC (B)”
“PRC”	the People’s Republic of China
“RMB”	Renminbi, the lawful currency of the PRC
“SFO”	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
“Shareholders”	the holders of the shares of the Company
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Supplemental Agreement”	the supplemental agreement to the 2017 Yuen Tai Master Distribution Agreement dated 28 September 2017 entered into between Yuen Tai and HK Kingworld to revise the maximum transaction amount contemplated under the 2017 Yuen Tai Master Distribution Agreement for the year ended 31 December 2017

“SZ Kingworld”	Shenzhen Kingworld Medicine Company Limited* (深圳市金活醫藥有限公司), a company established in the PRC with limited liability and a wholly-owned subsidiary of the Company
“SZ Kingworld Lifeshine”	Shenzhen Kingworld Lifeshine Pharmaceutical Company Limited* (深圳金活利生藥業有限公司), a company established in the PRC with limited liability
“SZ Kingworld Lifeshine Products”	certain pharmaceutical and healthcare products manufactured by SZ Kingworld Lifeshine including but not limited to the Kingworld Product Range and Imada Red Flower Oil
“Yuen Tai”	Yuen Tai Pharmaceuticals Limited (遠大製藥廠有限公司), a limited company incorporated under the laws of Hong Kong
“Yuen Tai Products”	certain pharmaceutical and healthcare products purchased or to be purchased by the Group from Yuen Tai including but not limited to (i) Fengbao Jianfu Capsule (鳳寶牌健婦膠囊); (ii) Pu Ji Kang Gan Granules (普濟抗感顆粒); and (iii) other products manufactured by Yuen Tai for digestion
“%”	per cent

The exchange rate adopted in this announcement is for illustration purpose only. Such conversion should not be construed as a representation that the currency could actually be converted at that rate.

By order of the Board
Kingworld Medicines Group Limited
Zhao Li Sheng
Chairman

Hong Kong, 20 November 2019

As at the date of this announcement, the executive Directors are Mr. Zhao Li Sheng, Ms. Chan Lok San, and Mr. Zhou Xuhua, and the independent non-executive Directors are Mr. Duan Jidong, Mr. Zhang Jianbin and Mr. Wong Cheuk Lam.

* *For identification purposes only*